Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Malar J ; 12: 441, 2013 Dec 06.
Article in English | MEDLINE | ID: mdl-24314037

ABSTRACT

BACKGROUND: Malaria treatment efforts are hindered by the rapid emergence and spread of drug resistant parasites. Simple assays to monitor parasite drug response in direct patient samples (ex vivo) can detect drug resistance before it becomes clinically apparent, and can inform changes in treatment policy to prevent the spread of resistance. METHODS: Parasite drug responses to amodiaquine, artemisinin, chloroquine and mefloquine were tested in approximately 400 Plasmodium falciparum malaria infections in Thiès, Senegal between 2008 and 2011 using a DAPI-based ex vivo drug resistance assay. Drug resistance-associated mutations were also genotyped in pfcrt and pfmdr1. RESULTS: Parasite drug responses changed between 2008 and 2011, as parasites became less sensitive to amodiaquine, artemisinin and chloroquine over time. The prevalence of known resistance-associated mutations also changed over time. Decreased amodiaquine sensitivity was associated with sustained, highly prevalent mutations in pfcrt, and one mutation in pfmdr1 - Y184F - was associated with decreased parasite sensitivity to artemisinin. CONCLUSIONS: Directly measuring ex vivo parasite drug response and resistance mutation genotyping over time are useful tools for monitoring parasite drug responses in field samples. Furthermore, these data suggest that the use of amodiaquine and artemisinin derivatives in combination therapies is selecting for increased drug tolerance within this population.


Subject(s)
Antimalarials/pharmacology , Drug Resistance/drug effects , Malaria, Falciparum/parasitology , Plasmodium falciparum/drug effects , Adolescent , Adult , Animals , Drug Resistance/genetics , Female , Humans , Inhibitory Concentration 50 , Male , Plasmodium falciparum/genetics , Prevalence , Reproducibility of Results , Senegal , Young Adult
2.
PLoS One ; 8(4): e60780, 2013.
Article in English | MEDLINE | ID: mdl-23593309

ABSTRACT

Using parasite genotyping tools, we screened patients with mild uncomplicated malaria seeking treatment at a clinic in Thiès, Senegal, from 2006 to 2011. We identified a growing frequency of infections caused by genetically identical parasite strains, coincident with increased deployment of malaria control interventions and decreased malaria deaths. Parasite genotypes in some cases persisted clonally across dry seasons. The increase in frequency of genetically identical parasite strains corresponded with decrease in the probability of multiple infections. Further, these observations support evidence of both clonal and epidemic population structures. These data provide the first evidence of a temporal correlation between the appearance of identical parasite types and increased malaria control efforts in Africa, which here included distribution of insecticide treated nets (ITNs), use of rapid diagnostic tests (RDTs) for malaria detection, and deployment of artemisinin combination therapy (ACT). Our results imply that genetic surveillance can be used to evaluate the effectiveness of disease control strategies and assist a rational global malaria eradication campaign.


Subject(s)
Malaria, Falciparum/epidemiology , Malaria, Falciparum/transmission , Plasmodium falciparum/genetics , DNA Barcoding, Taxonomic , Epidemics , Genetic Linkage , Genotype , Humans , Malaria, Falciparum/prevention & control , Multilocus Sequence Typing , Population Density , Prevalence , Seasons , Senegal/epidemiology
3.
Antimicrob Agents Chemother ; 56(6): 2976-86, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22430961

ABSTRACT

Despite efforts to reduce malaria morbidity and mortality, drug-resistant parasites continue to evade control strategies. Recently, emphasis has shifted away from control and toward regional elimination and global eradication of malaria. Such a campaign requires tools to monitor genetic changes in the parasite that could compromise the effectiveness of antimalarial drugs and undermine eradication programs. These tools must be fast, sensitive, unambiguous, and cost-effective to offer real-time reports of parasite drug susceptibility status across the globe. We have developed and validated a set of genotyping assays using high-resolution melting (HRM) analysis to detect molecular biomarkers associated with drug resistance across six genes in Plasmodium falciparum. We improved on existing technical approaches by developing refinements and extensions of HRM, including the use of blocked probes (LunaProbes) and the mutant allele amplification bias (MAAB) technique. To validate the sensitivity and accuracy of our assays, we compared our findings to sequencing results in both culture-adapted lines and clinical isolates from Senegal. We demonstrate that our assays (i) identify both known and novel polymorphisms, (ii) detect multiple genotypes indicative of mixed infections, and (iii) distinguish between variants when multiple copies of a locus are present. These rapid and inexpensive assays can track drug resistance and detect emerging mutations in targeted genetic loci in P. falciparum. They provide tools for monitoring molecular changes associated with changes in drug response across populations and for determining whether parasites present after drug treatment are the result of recrudescence or reinfection in clinical settings.


Subject(s)
Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Polymorphism, Single Nucleotide/genetics , Drug Resistance/genetics , Mutation , Parasitic Sensitivity Tests
4.
Acta Trop ; 121(3): 175-83, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22142790

ABSTRACT

With the paradigm shift from the reduction of morbidity and mortality to the interruption of transmission, the focus of malaria control broadens from symptomatic infections in children ≤5 years of age to include asymptomatic infections in older children and adults. In addition, as control efforts intensify and the number of interventions increases, there will be decreases in prevalence, incidence and transmission with additional decreases in morbidity and mortality. Expected secondary consequences of these changes include upward shifts in the peak ages for infection (parasitemia) and disease, increases in the ages for acquisition of antiparasite humoral and cellular immune responses and increases in false-negative blood smears and rapid diagnostic tests. Strategies to monitor these changes must include: (1) studies of the entire population (that are not restricted to children ≤5 or ≤10 years of age), (2) study sites in both cities and rural areas (because of increasing urbanization across sub-Saharan Africa) and (3) innovative strategies for surveillance as the prevalence of infection decreases and the frequency of false-negative smears and rapid diagnostic tests increases.


Subject(s)
Communicable Disease Control/methods , Disease Transmission, Infectious/prevention & control , Malaria, Falciparum/prevention & control , Plasmodium falciparum/pathogenicity , Africa, Western/epidemiology , Animals , Anopheles/parasitology , Antibodies, Protozoan/immunology , Antimalarials/pharmacology , Communicable Disease Control/legislation & jurisprudence , Communicable Disease Control/organization & administration , Drug Resistance, Microbial , Genotype , Humans , Immunity, Cellular , Incidence , Malaria, Falciparum/epidemiology , Malaria, Falciparum/immunology , Malaria, Falciparum/parasitology , National Health Programs/organization & administration , Parasitemia/epidemiology , Parasitemia/immunology , Parasitemia/parasitology , Parasitemia/prevention & control , Plasmodium falciparum/drug effects , Plasmodium falciparum/genetics , Plasmodium falciparum/immunology , Prevalence , Seasons , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...